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Sentinel lymph node biopsy (SLNB) is a safe and accurate minimally invasive method for detecting axillary lymph node (ALN)
involvement in the clinically negative axilla thereby reducing morbidity in patients who avoid unnecessary axillary lymph node
dissection (ALND). Although current guidelines recommend completion ALND when macro- and micrometastatic diseases are
identiﬁed by SLNB, the beneﬁt of this surgical intervention is under debate. Additionally, the management of the axilla in the
presence of isolated tumour cells (ITCs) in SLNB is questioned. Particularly controversial is the prognostic signiﬁcance of minimal
SLNB metastasis in relation to local recurrence and overall survival. Preliminary results of the recently published Z0011 trial
suggest similar outcomes after SNB or ALND when the SN is positive, but this ﬁnding has to be interpreted with caution.
1.Introduction
For patients with operable breast cancer, the major prognos-
tic determinant is whether there has or has not been spread
to the axilla and the number of involved axillary nodes [1].
Several theories exist concerning the mechanism of breast
cancer cell invasion and metastasis. Initially it was suggested
that breast cancer ﬁrst spreads locoregionally via lymphatics
to the axillary lymph nodes and then metastasises more
distantly. In accordance with this concept, Halsted developed
radical mastectomy as the gold standard for breast cancer
surgery [2].
Subsequently Fisher postulated that the extent of micro-
metastases at diagnosis of breast cancer is an indicator of
outcome, with biological behaviour of cancer predetermin-
ing the likelihood of progression of the disease [3]. Now-
adays gene expression proﬁling arrays can delineate tumour
types with diﬀerent prognoses [4]. The surgical approach for
breast cancer treatment evolved from the extensive radical
mastectomy and the Patey modiﬁed radical mastectomy [5]
to breast conserving and minimally invasive techniques [6].
Traditionally the surgical management of breast cancer
comprised wide local resection of the primary tumour and
axillary lymph node dissection (ALND). Axillary status
is the most important prognostic factor in breast cancer
providing staging information and therefore largely deﬁning
treatment strategy [7]. Diagnostic imaging modalities such
as ultrasound, magnetic resonance mammography, positron
emission tomography, and 99m Technetium (Tc) sestamibi
scintimammography are not reliable for staging the axilla,
particularly with lymph node metastases <0.5cm [8, 9].
Clinical, pathological, and molecular features are inad-
equate for assessing ALN metastases. Clinically palpable
lymph nodes prove to be false positive in 25–30% of patients
[10] and about 40% have positive results after ultrasound
with or without ﬁne-needle aspiration node negativity [11].
Tumoursizecannotserveasanaccurateprognosticindicator
for lymph node involvement. Studying 24,740 women with
invasive breast cancer, Carter et al. showed that approxi-
mately 80% with tumour size <1cm,50%withupto5cm,
and 30% with >5% had negative axilla, a fact suggesting that
metastases do not occur exclusively via the axillary lymph
nodes, but rather lymph node status serves as an indicator
of the tumour’s ability to spread [12]. Additionally, it has
beenrecentlyshownthatthemolecularproﬁleoftheprimary
tumour is a more signiﬁcant prognostic indicator in terms2 International Journal of Breast Cancer
of disease-free survival (DFS) and overall survival (OS) than
lymph node metastases [4].
The combination of the introduction of population-
based mammographic screening for breast cancer, modern
imaging methods, and increased public awareness resulted
in patients being diagnosed more often with smaller-size
tumours and less likelihood of axillary lymph node meta-
stases [13]. It is evident now that 60–70% of patients
with early breast cancer are node negative at the time of
diagnosis [14] and ALND puts them at signiﬁcant risk
of short- and long-term morbidities without beneﬁt [15].
ALND is associated with acute complication rates of 20–
30% including seroma formation, local swelling, numbness,
impaired shoulder movement, neuropathy, infection, and
chronic lymphoedema rates of 7–37% [16]. In a prospective
s t u d yb yP e t r e ke ta l . evaluating a cohort of 923 women with
20 years follow up, it was shown that breast-cancer-related
lymphoedema following ALND occurred maximally in the
ﬁrst3yearsfollowingsurgery;however,upto23%ofpatients
may still develop arm swelling during the rest of their lives
[17].
Several randomised studies have established that sentinel
node biopsy (SNB) is a safe and accurate procedure for de-
tecting tumour cells in SLN and predicting the status of the
other axillary nodes (non-SLN). Although accuracy and ap-
propriateness of SNB were disputed by the ﬁnding of 5–
10% false-negative cases when SNB was followed by axillary
dissection at high-risk patients for axillary nodal disease
[13, 18], false-negative SNB results seem to have decreased
with the increasing experience of surgeons, and it is expected
that the utilisation of SNB in the future will be increased
[19].
A meta-analysis of seven prospective randomised con-
trolled trials by Kell et al. demonstrated that SNB is equiv-
alent to ALND for the detection of lymph node metastasis
with the additional advantage of reduction of up to 75% in
morbidity in patients with early stage breast cancer. Further-
more, a trend towards an improved detection of LN metas-
tases was shown when SNB is used [20]. Patients undergoing
SNB have a 22% higher odds ratio of having a positive SLN,
due to the more intensive pathological examination which
utilises multiple sections and immunohistochemistry (IHC)
[21]. In contrast, the false-negative cases seen after axillary
dissection are probably due to the inability of the pathologist
to perform serial sections and IHC on the 20–30 lymph
nodes found in a complete axillary clearance specimen.
Studies have shown that SLN is the only positive
lymph node in 38–67% of patients when ALNC followed
[22]. Interestingly, it has been reported that only 4–8% of
patients with negative ALNs have internal mammary lymph
node involvement (IMN) whereas 25–50% of patients with
aﬀected ALNs have also IMN metastases [23, 24]. Dissection
of IMN is not recommended because of the high morbidity
and the uncertain beneﬁt on survival [24].
The recently published outcomes of NSABP B-32 trial
established the eﬃcacy of SLN biopsy alone with no further
ALND in 5611 breast cancer patients with clinically negative
lymph nodes [25]. Women with invasive breast cancer
who were randomly assigned to either SLN resection plus
ALND (group 1) or to SLN resection alone with ALND
only if the SLNs were positive (group 2), after 8 years
of followup, showed statistically equivalent overall survival,
disease-free survival, and regional control. Patient followup
is still continuing for longer-term assessment of survival and
regional control.
Moreover, a closer look into mature studies focused on
axillaryrelapsesandoverallsurvivalisinagreementwithcur-
rent ﬁndings favouring SLB. The National Surgical Adjuvant
Breast and Bowel Project (NSABP) B04 randomised study
compared breast cancer patients with clinically negative
ALNs managed either by radical mastectomy, total mastec-
tomy with axillary radiation, or total mastectomy alone. The
results clearly deﬁned that ALND decreases the risk of loco-
regionalrelaps;however,nosigniﬁcantdiﬀerencesinsurvival
were found among the treatment groups [26]. This study
has been criticised because of the variability of numbers of
lymph nodes resected in the total mastectomy alone arm
and the lack of statistical power to detect a small diﬀerence
in outcome [27]. Indeed, a meta-analysis has suggested that
inadequate axillary treatment may lead to not only an in-
creased risk of local relapse but also a 5% reduction in
survival [28].
As a result of increasing detection of early breast cancer
and the high rate of micrometastases and ITCs (ITCs) found
in the detailed pathological examination of SLN, a new
debate has opened about the consequent necessity of ALND
in these patients. This has arisen because of better under-
standing of breast cancer behaviour and improved eﬃcacy
of combined therapeutic modalities. In this paper we report
the current guidelines concerning the management of the
axilla after SLNB and review the diﬀerent aspects arising
from recent studies on the role of micrometastases and ITC
clusters in SLN on decision making.
2. CurrentGuidelines
The American Society of Clinical Oncology (ASCO) Expert
Panel conducted a systematic review of the literature avai-
lable through February 2004 on the use of SNB in early-
stage breast cancer in order to develop guidelines for the
management of the axilla (http://jop.ascopubs.org/content/
1/4/134) and these are similar to those of the National
Institute of Health and Clinical Excellence (NICE) rec-
ommendations in UK (http://www.nice.org.uk/nicemedia/
live/12132/43413/43413.pdf)[ 29].
SLNBisrecommendedforstagingpatientswithclinically
negative lymph nodes. ALND is the standard of care in those
with a macrometastatic or micrometastatic positive SLN to
maximise local control [30]. If the SLN is negative, a cALND
(cALND) is not necessary. ITCs detected by IHC are of
unknown clinical signiﬁcance, and when identiﬁed, the SLN
is regarded as negative and no further ALND is required.
Although IHC is often used, it is not included in routine SLN
evaluation for breast cancer at this time. ASCO and NICE
recommendations for SLNB, ALND alone and managing of
the axilla after SLNB are summarised in Table 1.I nc o n t r a s t
the German guidelines do not recommend axillary clearanceInternational Journal of Breast Cancer 3
for 1-2 SLN positive in patients with T1 and T2 tumours
(http://www.ago-online.de).
It has been suggested that SLNB should be carried out
by an experienced team in order to minimise false negativity
and improve the predictive value of the procedure [30]. All
suspiciouspalpablenodesshouldalsobeconsideredasSLNs.
3.MicrometastasesandIsolatedTumour
Cells(ITCs)
The American Joint Committee on Cancer (AJCC) in the
sixth edition of the Cancer Staging Manual deﬁned a lymph
node metastatic tumour with maximum diameter > 2mm
as macrometastasis (pN1), when the diameter of deposit is
0.2–2mm as micrometastasis (pNmi), and a lesion of single
tumour cells or small cell clusters with diameter < 0.2 mm
as ITCs [pN0(i+)] [31]. ITCs are not distinguishable by
H&E staining but detected only with immunohistochemistry
(IHC) or molecular methods. Moore et al. suggested that the
presence of ITCs was unrelated to known prognostic var-
iables and partly the result of instrumentation and mani-
pulation of the tumour [32].
The management of patients with minimal SLN involve-
ment is problematic [33]. In a meta-analysis of 25 studies of
patients with SLN micrometastases, in approximately 20%
there was nonsentinel node disease falling to 9% when the
SLN involvement was detected by IHC [34]. Furthermore,
the consequent eﬀect on DFS and OS remains controversial,
sothebiologicalrelevanceandclinicalsigniﬁcanceisamatter
of debate [35].
AMAROS investigates the beneﬁt of a cALND in com-
parison to treatment with axillary radiotherapy (ART) in
patients with SLN-positive breast cancer [36]. A recently
published substudy evaluated the identiﬁcation rate and the
nodal involvement of the ﬁrst 2,000 patients between 2001
and 2005 who entered from 26 European institutions [36].
The sentinel node identiﬁcation rate was 97% which is high
considering the relatively early days of this procedure. 34%
were SLN positive of whom 63% had macrometastases, 25%
had micrometastases, and 12% had ITCs. In the cALND arm
non-SLN involvement was identiﬁed in 41% of patients with
macrometastases and in 18% of patients with either micro-
metastases or ITCs.
Severalstudieshaveinvestigatedthesigniﬁcanceofoccult
metastases, such as micrometastases or small clusters of tu-
mour cells in association with non-SLN involvement and
the impact of cALND on disease-free survival and overall
survival, and the larger ones are summarised in Table 2
[37–43]. Although the majority show no prognostic impact
of ITCs in the sentinel node, a large Dutch investigation
with 5-year followup indicated that women with ITCs who
received adjuvant chemotherapy had a signiﬁcantly better
event-free survival compared with untreated cases with ITCs
[39]. Furthermore, a Finnish study showed a worse 5-year
breast-cancer-speciﬁc survival for those with ITC compared
with node negative cases [42].
In the largest published multicenter retrospective study
of 187 SLN-ITCs patients undergoing cALND, Houve-
naegheletal.reportedanincidenceof16%non-SLNinvolve-
ment [44]. The diﬀerence in the risk of non-SLN involve-
ment between sentinel nodes with ITCs (16%) and those
with micrometastases (14%) was not statistically signiﬁcant.
However it was not apparent whether the presence of non-
SLN metastases should aﬀect the therapeutic decision in
these patients. The authors proposed that cALND could be
avoided in patients with tubular, colloid, or medullary small
primary tumours (pT1) with a risk of non-SLN involvement
approximately ≤ 5%.
In contrast to the conclusions of the aforementioned
studies come the MIRROR trial results [45]. MIRROR is a
large Dutch cohort retrospective study which assesses the
impact of SLN-ITCs and micrometastases on 5-year disease-
free survival in patients with favourable primary tumour
characteristics. According to recent published data, both
patients with SNB micrometastases and those with ITCs who
did not undergo cALND experienced a far higher 5-year
axillary recurrence rate, 6% in comparison to 1% of SNB-
negative patients who did not undergo cALND. Additionally,
both patients with SLN micrometastases and ITCs had ap-
proximately 5-year disease-free survival improved by 10%
with adjuvant systemic therapy. It is important to mention
that micrometastases and ITCs had comparable prognostic
impact [46]. MIRROR ﬁndings support an aggressive treat-
ment approach in patients with either SLN micrometastases
or ITCs.
4. Completion ALND and Micrometastases
Many investigators have studied the incidence of non-
SLN involvement in patients with SLN micrometastases to
deﬁne which patients may need further axillary treatment.
Wada and Imoto. collected 22 studies from 1999 until
2006 referring to the frequency of SLN micrometastases
in patients with breast cancer and the prevalence of non-
SLN involvement in those patients after ALND [47]. The
frequency of SLN micrometastases was 38% with non-SLN
micrometastases ranging from 0 to 57%. Additionally, a wide
range of non-SLN macrometastases was found (0–18%).
Because the prevalence of non-SLN micrometastases was
low, the prognostic impact was unclear. The wide range of
results arose from the diﬀerent numbers of patients involved,
variations in number of pathological sections examined, and
diﬀerences in tumour stage and grade.
Resultsofstudies in whichpatients withmicrometastases
in SNB and who were not treated by completion axillary
node clearance are summarised in Table 3 [38, 48–54].
Most of the studies had small numbers and relatively short
followup and tended to conclude that there was no beneﬁt
from completion axillary node clearance. The largest study;
however, found a signiﬁcantly worse disease-free survival for
women with micrometastases who did not undergo cALND.
[38].
DeBoeretal.conductedasystematicreviewof58studies
conducted from 1977 to 2008 included 297,533 patients,4 International Journal of Breast Cancer
Table 1: Recommendations of SLNB, ALND, and treatment after SLNB.
SLNB ALND Post-SLNB
T1, T2 tumour T3, T4 tumours SLNB +ve ALND
Multicentric tumour Inﬂammatory carcinoma SLNB −ve Observe
DCIS for mastectomy Suspicious axillary node Micromets ALND
DCIS > 5cm Pregnancy ITC Observe
Older patient Prior axillary surgery SLNB +ve, 1-2 nodes, T1, T2 Observe∗
Preneoadjuvant
DCIS: ductal carcinoma-in-situ; SNB: sentinel lymph node biopsy; ALND: axillary lymph node dissection.
∗Recommendation of the German guidelines.
Table 2: Incidence and prognostic impact of ITCs in sentinel node biopsies.
Author Total ITC (%) Outcome
Herbert et al. [37] 514 16 (3%) No eﬀect
Reed et al. [38] 1255 25 (2%) No eﬀect
De Boer et al. [39] 2707 819 HR 1.5 (No adjuvant versus adjuvant)
Barbosa et al. [40] 1000 43 (4%) No eﬀect
Andersson et al. [41] 3369 107 (3%) No eﬀect
Leidenius et al. [42] 1390 63 (5%) Reduced 5-year survival
Maaskant-Braat et al. [43] 6803 126 (2%) No eﬀect
aimingtodeﬁnetheprognosticrelevanceofmicrometastases
and ITCs in patients with breast cancer [55]. Using random-
eﬀect meta-analysis they showed that the presence of ALN
metastases <2mm in diameter detected on single-section
examination was associated with poorer overall survival.
Moreover the presence of occult metastases on retrospective
examination of ALN-negative patients by step sectioning
and/orimmunohistochemistry(n = 7740patients)wasasso-
ciated with poorer 5-year disease-free and overall survival.
Outcomes from sentinel lymph node biopsy studies were not
assessable due to small patient groups and short followup.
The International Breast Cancer Study Group trial
IBCSG-23-01 is a randomised multicentre study designed to
determine the signiﬁcance of minimal LN metastasis in pa-
tients with breast cancer [56]. The trial was initiated in April
2001, and it compares survival between patients with SLN
micrometastases who undergo SLNB alone with those who
receive cALND.
5. Completion AxillaryLymph Node Dissection
inSLNMacrometastases
It is known that the extent of macrometastases in SLN is
strongly correlated with non-SLN involvement. The long-
term eﬀect of the residual axillary disease in the sentinel-
lymph-node-positive patient on local and systemic recur-
rence has not been clearly deﬁned for patients receiving
modern radiotherapy and chemotherapy. Older studies of
patients with symptomatic breast cancers have shown that
inadequate axillary surgery does lead to reduced overall
survival [57–60].
Recently, the ﬁrst results of the multicentre Z0011
trial were published [61]. The study set out to randomise
1900women with breast cancer and 1–5 involved SNLN to
either cALND or observation. All had a lumpectomy and
tangential breast irradiation, but systemic therapy was at the
discretion of the treating centre. After a median followup
of 6.3years, the relapse-free survival for the ALND group
was 82% compared with 84% for the observation group, and
the overall survival was 92% in both groups. Unfortunately
the trial stopped accrual after 891 cases had been entered
which makes it underpowered to detect a 5% diﬀerence in
outcome. An additional aspect to be considered is that the
Guy’swideexcisionstudiesshowednodiﬀerencebetweenthe
wide excision group and the radical mastectomy group at 10
years whereas after 25 years there was a signiﬁcantly worse
relapse-free and overall survival in the wide excision group
with inadequately treated axillae [58].
In a retrospective study, Takei etal. conﬁrmedthe impor-
tance of cALND in SLN-positive patients with high nuclear
grade and hormone-negative breast cancer. It was noticed
that of 459 patients with macrometastatic disease treated
with cALND, after a median follow-up period of 34months,
the axillary recurrence rate was only 0.6% [62]. Bilimoria
et al. studied a cohort of 403,167 patients with clinically
node-negative breast cancer that underwent SLNB from
the US National Cancer Data Base (1998–2005) [63]. Of
the 97,314 (24%) patients identiﬁed with nodal metastases,
28% had no further surgical intervention in the axilla
and 72% underwent cALND. After a median followup of
63months, it was found that in all patients and separately
in those with macroscopic and microscopic nodal disease,
the unadjusted axillary recurrence rate and overall survival
were comparable. After adjustment for clinicopathological
diﬀerences, there was a trend towards a lower risk of axillary
recurrence and death in patients with macroscopic nodalInternational Journal of Breast Cancer 5
Table 3: Studies of patients with micrometastases not treated by completion mastectomy.
Author Total Follow-up (months) Outcome
Fan et al. [48]2 7 1 7 1 r e c u r r e n c e
Nagashima et al. [49]1 9 2 4 1 r e c u r r e n c e
Yegiyants et al. [50]3 3 8 4 1 r e c u r r e n c e
Fournier et al. [51] 16 30 No recurrence
Langer et al. [52] 27 77 No recurrence
Meretoja et al. [53] 48 37 3 recurrences, 1 death
Pernas et al, [54]4 5 6 0 1 r e c u r r e n c e
Reed et al. [38] 57 59 Signiﬁcantly reduced disease-free interval
involvement undergoing cALND. For those with micrometa-
stases, recurrence rates were similar in those undergoing
either SLNB alone or cALND.
Of 26,986 patients with SLNB-positive breast cancer
fromtheSEERdatabase(surveillance,epidemiology,andend
results), 16% had no further axillary treatment and 84%
had cALND [64]. After a median followup of 50 months,
although a higher rate of ipsilateral regional recurrence was
noticed in patients who underwent SLNB alone, no statisti-
cally signiﬁcant diﬀerences in overall survival (OS) between
patients who underwent SLNB alone versus complete ALND
were found. The investigators suggested that in patients with
small, low-grade primary tumours, positive ER status, older
age and who have received segmental mastectomy, cALND
may be omitted [64].
Hwangetal.reviewedtheoutcomeof3,366 patientswith
invasive breast cancer who underwent SLNB from 1993 to
2005 [65]. Of 750 SLN-positive patients, 65%, 45.9%, and
34.2%werepN1,pN1mi,andpN0(i+),respectively.Ofthese
patients, 196 had no further axillary surgery due to clinician
and patient preference. According to clinicopathological
variables, adjuvant treatment was applied and locoregional
and distant recurrence and survival were studied. After a
median followup of 29.5 months, no patient had an axillary
recurrence, one had supraclavicular lymph node recurrence,
and three patients developed metastatic disease to the lung
or bone. The median time to recurrence was 32 months.
Notably the patients with distant metastases had T3 grade III
invasive carcinoma. Despite the low axillary recurrence rate,
authors suggested that it is not possible from these results to
conclude deﬁnitively that cALND should be abandoned for
these patients [65].
6.PredictiveModels
Several factors correlated with the likelihood of additional
non-SLN metastasis have been investigated in an eﬀort to
distinguish which patients could avoid extensive axillary
surgery. Characteristics of the primary tumour, such as size
[40, 66], grade [67], hormone receptor and HER2 proﬁle
[67], tumour type [67], multifocality, mean proliferative
fraction, and lymphovascular invasion [68, 69], have all been
studied.AdditionalfeaturesoftheinvolvedSLNs,suchassize
of metastases [40], number of positive SLNs [40], ratio of
positive to resected SLNs, and the extracapsular spread have
Table 4: Major prognostic factors for non-SLN metastases in
patients with minimal SLN metastases.
Feature Author
Lymphovascular
invasion
Mittendorf et al. [67],
Van Deurzen et al. [66],
Viale et al. [69],
Jinno et al. [68]
Size of SLN
metastases
Barbosa et al. [40],
Van Deurzen et al. [66],
Viale et al. [69]
Primary tumour
size
Barbosa et al. [40],
Van Deurzen et al. [66]
Lobular
histology Mittendorf et al. [67]
Number of
positive SLN
Barbosa et al. [40],
Viale et al. [69],
Jinno et al. [68]
been also examined [21, 61, 70–72]. Particularly patients
with minimal SLN metastases are at a signiﬁcantly lower
risk to have further non-SLN invasion than those with SLN
macrometastases (13–24% versus 45–79%) [61]. However,
none of these characteristics individually can determine a
subsetofpatientsforwhomALNDisunnecessary.Molecular
proﬁling of metastatic foci diﬀerent from the primary
tumour could be used as indicator for the selection of
patients who might beneﬁt of completion axillary dissection
[73]. The most important prognostic factors for the presence
of non-SLN metastases in patients with minimal SLN
involvement are presented in Table 4.
Several mathematical models have been developed to
predict the risk of non-SLN involvement in patients
with SLN-positive breast cancer [74]. These include four
nomograms: the Memorial Sloan-Kettering Cancer Center
(MSKCC) [75], (https://www.mskcc.org/mskcc/html/15938
.cfm), Mayo [76]( http://www.mayoclinic.org/breast-cancer/
sentinelbiopsy.html), Cambridge [77] ,a n dS t a n f o r d[ 70]
(https://www3-hrpdcc.stanford.edu/nsln-calculator/). There
are three scoring systems, the Tenon, MDA, and Saidi, and
two recursive partitioning (RP) tools developed by Kohrt
et al. [70].
The Institut Curie studied 588 consecutive patients with
positive SLNs who underwent ALND to compare the actual6 International Journal of Breast Cancer
Table 5: Validation studies comparing OSNA with histopathology.
Author Total Concordance Sensitivity Speciﬁcity
Tsujimoto et al. [71] 101 98% 91% 100%
Schem et al. [72] 93 92% 98% 91%
Tamaki et al. [79] 185 93% 88% 94%
Snook et al. [80] 204 96% 92% 97%
Feldman et al. [81] 498 96% 78% 96%
rate of non-SLN metastases with those predicted by Breast
Cancer Nomogram of Memorial Sloan-Kettering Cancer
Center (MSKCC). While the predicted rate in non-SLN
macrometastases was relatively accurate, when the nomo-
gram was applied to the 213 SLNs that contained only
micrometastases, the predicted rate 5–9% was far away from
the actual rate 44% of non-SLN micrometastases detect-ed
by IHC. Consequently, the authors concluded that a diﬀer-
ent predictive model should be created for patients with
micrometastases.
Molecular tests based on technology such as Oncotype
Dx (Genomic Health, Redwood City, Calif, USA) or other
multigene arrays developed prognostic and predictive mark-
ers aiming to personalize surgical and adjuvant treatment of
early breast cancer [4]. An accurate, intraoperative sentinel
lymph node test probably could help in avoidance of delayed
axillarydissections.Moleculartestsmaybeprovedmoresen-
sitive than current intraoperative tests but have not yet been
validated.
7. One-Step NucleicAcidAmpliﬁcation (OSNA)
OSNA is an automated assay for the detection of cytokeratin
message, CK19 mRNA, present in approximately 98% of
breast cancers [78]. It provides an opportunity to make an
intraoperative diagnosis of sentinel node involvement within
30minutes, avoiding frozen section and allowing a one-
stage procedure. Larger veriﬁcation studies in which half of
the bisected sentinel node was sent for histology and the
other half homogenised for OSNA are shown in Table 5
[71, 72, 79–81]. The usual reason for discordance between
histopathology and OSNA was an uneven distribution of
nodal metastases (tissue allocation bias). This problem is
abolished when the entire node is subjected to OSNA.
The studies indicate a good concordance between results
of histopathology and OSNA. Indeed in a study conducted
by Osaka, comparing OSNA with frozen section, the former
was more sensitive, increasing the positive sentinel node
rate by 30% [82]. It is likely that in time OSNA will re-
place histopathological examination of sentinel lymph nodes
because of its ease, accuracy, and potential for enabling
almost all patients to have a one-stage operation for early
breast cancer.
8. Conclusions
Recent studies aiming to determine if cALND is beneﬁcial
in patients with SLN-positive breast cancer and even more
in patients with minimal SLN involvement have reached
contrary conclusions. Limitations in the published studies
include the methods of pathological evaluation of lymph
nodes and that the number of additional non-SLN-positive
nodes is usually not known. Detection rate of micrometas-
tases and ITCs depends on histopathological technique and
protocol. Thus lymph node step sectioning and IHC lead
to increased identiﬁcation of minimal metastases upstaging
9% to 25% of patients who initially were considered node
negative [83, 84] and did not have further axillary surgery.
The diﬀerent rates of recurrence may be due to the
molecular type of cancers and so that patients with SLN
metastasesmayalsohavediﬀerentrisksofmetastaticinvolve-
ment [40]. Finally it is possible that not all minor tumour
foci in axillary lymph nodes progress to local recurrences.
According to Al-Hajj et al., only a minority of cancer cells
potentially give metastases and most ITCs are not viable and
do not have the ability to form new tumours [85]. There may
betwodiﬀerentbreastcancercellpopulations,truestemcells
thathavethecapacitytodevelopmetastasesandthenonstem
cells that never grow and are ﬁnally destroyed [86].
At the level of everyday clinical practice, with both
promisinganddisappointingresultsofthepublishedstudies,
mostbreastsurgeonswillhardlyevertaketheriskofavoiding
completion axillary dissection in breast cancer patients even
with minimal sentinel lymph node metastases. Many are
seeking to ﬁnd a balance between the needs of the majority
to have minimal axillary surgery with minimal postoperative
morbidity against the possibility that a minority will suﬀer
relapse, morbidity, and possible increased mortality from
undertreatment. Results from ongoing phase III trials will
perhaps provide new guidelines for the treatment of patients
with micrometastases or ITCs. A predictive model which
estimates accurately the likelihood of additional disease in
the axilla might help tailor surgical therapy to the needs
of the individual patient and identify those most likely to
beneﬁt from completion or ALND. Genetic assays deﬁning
prognostic markers and new intraoperative tests detecting
accurately SLN involvement will help in early therapeutic
decision making in the future. It is important that premature
decisions to restrict axillary surgery are not made on a basis
of early results from underpowered clinical trials.
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